Drug Profile
CBT 001
Alternative Names: CBT-001Latest Information Update: 19 Jul 2022
Price :
$50
*
At a glance
- Originator Cidara Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Immunostimulants; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Recurrent pterygium
Most Recent Events
- 30 Jun 2022 Phase-III clinical trials in Recurrent pterygium (In adults, In adolescents, In the elderly) in USA (Ophthalmic, Drops) (NCT05456425)
- 16 Mar 2021 CBT 001 is still in phase I trial for Recurrent pterygium in USA (Ophthalmic) (Cloudbreak Therapeutics pipeline, March 2021)
- 30 Apr 2018 Cloudbreak Therapeutics completes a phase II trial in Recurrent pterygium in USA (Ophthalmic) (NCT03049852)